New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F23%3A00083946" target="_blank" >RIV/00023001:_____/23:00083946 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/23:10464481 RIV/00216208:11110/23:10464481 RIV/00064203:_____/23:10464481 RIV/00064190:_____/23:10001198

Result on the web

<a href="https://portlandpress.com/clinsci/article/137/9/727/233062/New-insights-into-the-pathophysiology-and" target="_blank" >https://portlandpress.com/clinsci/article/137/9/727/233062/New-insights-into-the-pathophysiology-and</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1042/CS20190281" target="_blank" >10.1042/CS20190281</a>

Result language

angličtina

Original language name

New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis

Original language description

Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) or without (CRSsNP) are chronic respiratory diseases. These two disorders often co-exist based on common anatomical, immunological, histopathological, and pathophysiological basis. Usually, asthma with comorbid CRSwNP is driven by type 2 (T2) inflammation which predisposes to more severe, often intractable, disease. In the past two decades, innovative technologies and detection techniques in combination with newly introduced targeted therapies helped shape our understanding of the immunological pathways underlying inflammatory airway diseases and to further identify several distinct clinical and inflammatory subsets to enhance the development of more effective personalized treatments. Presently, a number of targeted biologics has shown clinical efficacy in patients with refractory T2 airway inflammation, including anti-IgE (omalizumab), anti-IL-5 (mepolizumab, reslizumab)/anti-IL5R (benralizumab), anti-IL-4R-alpha (anti-IL-4/IL-13, dupilumab), and anti-TSLP (tezepelumab). In non-type-2 endotypes, no targeted biologics have consistently shown clinical efficacy so far. Presently, multiple therapeutical targets are being explored including cytokines, membrane molecules and intracellular signalling pathways to further expand current treatment options for severe asthma with and without comorbid CRSwNP. In this review, we discuss existing biologics, those under development and share some views on new horizons.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30102 - Immunology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Clinical science

ISSN

0143-5221

e-ISSN

1470-8736

Volume of the periodical

137

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

27

Pages from-to

727-753

UT code for WoS article

000995806600001

EID of the result in the Scopus database

2-s2.0-85159760053